Non-systemic drugs: A critical review

Current Pharmaceutical Design

Volumn 18, Issue 10, 2012, Pages 1434-1445

  Charmot, Dominique ^a  

^a Ardelyx Inc   (United States)

Author keywords

Absorption; Gastrointestinal tract; Non absorbed drugs; Non systemic drugs; Tight junctions

Indexed keywords

AST 120; BACTERIUM LIPOPOLYSACCHARIDE; BILE ACID SEQUESTRANT; CLOSTRIDIUM DIFFICILE TOXIN A; COLESEVELAM; DEFERASIROX; DEFEROXAMINE MESYLATE; EZETIMIBE; INTESTINE ENZYME; LARAZOTIDE; PHOSPHATE BINDING AGENT; PHOSPHOLIPASE A2 INHIBITOR; PLACEBO; POLYSTYRENESULFONATE CALCIUM; POLYSTYRENESULFONATE SODIUM; POTASSIUM; TETRAHYDROLIPSTATIN; UREMIC TOXIN;

ARTICLE; CELIAC DISEASE; DETOXIFICATION; DRUG ABSORPTION; DRUG DISPOSITION; DRUG MECHANISM; DRUG METABOLISM; GASTROINTESTINAL TRACT; HUMAN; HYPERKALEMIA; HYPEROXALURIA; INTESTINE MUCOSA PERMEABILITY; IRON OVERLOAD; LIFESTYLE MODIFICATION; METABOLIC DISORDER; MINERAL METABOLISM; NONHUMAN; OBESITY; PHARMACODYNAMICS; PRIORITY JOURNAL; STEATORRHEA; TIGHT JUNCTION; TISSUE DISTRIBUTION;

EID: 84857771313     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799504858     Document Type: Article

References (139)

1. Bodor N, Buchwald P: Recent advances in retrometabolic drug design (RMDD) and development. Pharmazie 2010, 65:395-403.
2. Bodor N, Buchwald P: Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites. Mol.Biotechnol. 2004, 26:123-32.
3. Bodor N: Retrometabolic drug design--novel aspects, future directions. Pharmazie 2001, 56 Suppl 1:S67-74.
4. Bodor N, Buchwald P: Soft drug design: general principles and recent applications. Med.Res.Rev. 2000, 20:58-101.
5. Lennernas H: Intestinal permeability and its relevance for absorption and elimination. Xenobiotica 2007, 37:1015-51.
6. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv.Drug Deliv.Rev. 2001, 46:3-26.
7. Ertl P, Muhlbacher J, Rohde B, Selzer P: Web-based cheminformatics and molecular property prediction tools supporting drug design and development at Novartis. SAR QSAR.Environ.Res. 2003, 14:321-8.
8. Ertl P, Rohde B, Selzer P: Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J.Med.Chem. 2000, 43:3714-7.
9. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD: Molecular properties that influence the oral bioavailability of drug candidates. J.Med.Chem. 2002, 45:2615-23.
10. Florence AT: Nanoparticle uptake by the oral route: Fulfilling its potential? Drug Discovery Today: Technologies 2005, 2:75-82.
11. Heller DP, Burke SK, Davidson DM, Donovan JM: Absorption of colesevelam hydrochloride in healthy volunteers. Ann.Pharmacother. 2002, 36:398-403.
12. Plone MA, Petersen JS, Rosenbaum DP, Burke SK: Sevelamer, a phosphate-binding polymer, is a non-absorbed compound. Clin Pharmacokinet 2002, 41:517-23.
13. van Nueten JM, Helsen L, Michiels M, Heykants JJ: Distribution of loperamide in the intestinal wall. Biochem.Pharmacol. 1979, 28:1433-4.
14. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat.Rev.Drug Discov. 2010, 9:215-36.
15. SalixPharmaceuticals: Rifaximin package insert http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/GastrointestinalDrugsAdvisoryCommittee/UCM201081.pdf 2010.
16. Roffey SJ, Obach RS, Gedge JI, Smith DA: What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev. 2007, 39:17-43.
17. van Itallie CM, Holmes J, Bridges A, et al. The density of small tight junction pores varies among cell types and is increased by expression of claudin-2. J.Cell Sci. 2008, 121:298-305.
18. Hossain Z, Hirata T: Molecular mechanism of intestinal permeability: interaction at tight junctions. Mol.Biosyst. 2008, 4:1181-5.
19. Salamat-Miller N, Johnston TP: Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. Int.J.Pharm. 2005, 294:201-16.
20. Levy G: The development of pharmacodynamics as a pharmaceutical science: a personal perspective. Ann.Pharmacother. 2006, 40:520-23.
21. Hoad CL, Marciani L, Foley S, et al. Non-invasive quantification of small bowel water content by MRI: a validation study. Phys.Med.Biol. 2007, 52:6909-22.
22. Marciani L, Cox EF, Hoad CL, et al. Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome. Gastroenterology 2010, 138:469-77.
23. Carriere F, Renou C, Ransac S, et al. Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers. Am.J.Physiol Gastrointest.Liver Physiol 2001, 281:G16-28.
24. Burke SK, Slatopolsky EA, Goldberg DI: RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant 1997, 12:1640-4.
25. Hutchison AJ, Smith CP, Brenchley PE: Pharmacology, efficacy and safety of oral phosphate binders. Nat.Rev.Nephrol. 2011, 7:578-89.
26. Akizawa T, Kameoka C: Long-term treatment of Bixalomer in chronic kidney disease patients on hemodialysis with hyperphosphatemia. Proceeding of ASN meeting 2011 Philadelphia JASN Abstract Supplement 2011, 22:FR-PO1667.
27. Chang H, Charmot D, Connor E, Roger F, inventors, Ilypsa Inc, Assignee: Crosslinked amine polymers. United States Patent 7767768B2 2010.
28. Sabbagh Y, O'Brien SP, Song W, Boulanger JH, Stockmann A, Arbeeny C, Schiavi SC: Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J.Am Soc.Nephrol. 2009, 20:2348-58.
29. Henley C, Davis J, Lee P, Wong S, Salyers K, Wagner M: A small molecule, non-competitive inhibitor of sodium-phosphate (NaPi2b) with low oral bioavailability attenuates cellular and intestinal phosphate transport and reduce serum phosphate in hyperphosphatemic rats. Proceedings of the XLVIII ERA-EDTA Congress, Prague 2011 http://www.abstracts2view.com/era/view.php?nu=ERA11L_996 2011.
30. Navre M, Labonte ED, Carreras C, et al: Novel Non-Systemic NaP2b Inhibitors Block Intestinal Phosphate Uptake. Proceedings of ASN meeting 2011, Philadelphia, JASN Abstract Supplement 2011, 22:TH-OR020.
31. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J.Clin.Invest 2011, 121:4393-408.
32. Sandle GI, Hunter M: Apical potassium (BK) channels and enhanced potassium secretion in human colon. QJM. 2010, 103:85-9.
33. Nanda Kumar NS, Singh SK, Rajendran VM: Mucosal potassium efflux mediated via Kcnn4 channels provides the driving force for electrogenic anion secretion in colon. Am.J.Physiol Gastrointest.Liver Physiol 2010, 299:G707-14.
34. FDA: Kayexalate (sodium polystyrene sulfonate) powder. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm186845.htm 2011.
35. Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ: Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur.Heart J. 2011, 32:820-8.
36. Charmot D, Chang H, Klearner G, Cope J, Liu M, Liu F, et al, Inventors, ILypsa Inc, Assignee: Ion binding polymers and uses thereof. European Patent Application 2269589A3 2011.
37. Simon J, Strickland AD, Inventors, Dow Global Technologies Inc., Assignee: In vivo use of water absorbent polymers. United States Patent S6908609B2 2005.
38. Liu F, Chang H, Charmot D, Liu M, Connor E, Inventors, Ilypsa Inc, Assignee: Monovalent cation-binding compositions comprising core-shell particles having crosslinked polyvinylic shells, and methods of use thereof. WO 2007038801A2 2007.
39. Slagman MC, Waanders F, Hemmelder MH, Woittiez AJ, Janssen WM, Lambers Heerspink HJ, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ 2011, 343:d4366.
40. McChesney EW, Nachod FC, Tainter ML: Some aspects of cation exchange resins as therapeutic agents for sodium removal. Ann N Y Acad Sci 1953, 57:252-9.
41. Orgain ES: Cation exchange resins in congestive heart failure. Med Clin North Am 1954, 11:419-30.
42. Spencer AG, Navre M, Plato CF, et al: RDX5791, a Non-Systemic NHE3 Inhibitor, Normalizes Blood Pressure and Reduces Salt-Induced Organ Damage in Uremic Rats. Proceeding of ASN meeting 2011 Philadelphia JASN Abstract Supplement 2011, 22:SA-OR430.
43. Mandeville H, Holmes-Farley SR, Inventors, GelTex Pharmaceuticals Inc., Assignee: Iron-binding polymers for oral administration. United States Patent 5487888 1994.
44. Polomoscanik SC, Cannon CP, Neenan TX, et al. Hydroxamic acid-containing hydrogels for nonabsorbed iron chelation therapy: synthesis, characterization, and biological evaluation. Biomacromolecules. 2005, 6:2946-53.
45. Shayeghi M, Latunde-Dada GO, Oakhill JS, et al. Identification of an intestinal heme transporter. Cell 2005, 122:789-801.
46. Filippatos TD, Mikhailidis DP: Lipid-lowering drugs acting at the level of the gastrointestinal tract. Curr.Pharm.Des 2009, 15:490-516.
47. Rucker D, Padwal R, Li SK, Curioni C, Lau DC: Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007, 335:1194-9.
48. Mandeville H, Boie M, Allston MA, Garigapati VR, inventors, GelTex Pharmaceuticals Inc., Assignee: Lipase inhibiting polymers. United States Patent 6572850B1 2003.
49. Jozefiak T, Holmes Farley S, Mandeville H, et al, Inventors, GelTex Pharmaceuticals Inc., Assignee: Fat-binding polymers. United States Patent 6299868B1 2001.
50. M: NPC1L1 as the target of Ezetimibe. Abstracts of Papers, 239th ACS National Meeting, San Francisco, CA, United States, March 21-25, 2010 2010, MEDI-280.
51. Betters JL, Yu L: NPC1L1 and cholesterol transport. FEBS Lett. 2010, 584:2740-7.
52. Reboul E, Goncalves A, Comera C, et al. Vitamin D intestinal absorption is not a simple passive diffusion: evidences for involvement of cholesterol transporters. Mol.Nutr.Food Res. 2011, 55:691-702.
53. Wang Y, Haiqian, Huang W, Zhang H, Zhou J: Synthesis and biological evaluation of ezetimibe analogs as possible cholesterol absorption inhibitors. Lett.Drug Des.Discovery 2011, 8:500-5.
54. Howell KL, DeVita RJ, Garcia-Calvo M, et al. Spiroimidazolidinone NPC1L1 inhibitors. Part 2: Structure-activity studies and in vivo efficacy. Bioorg.Med.Chem.Lett. 2010, 20:6929-32.
55. Morriello GJ, Moyes CR, Lin P, et al. Discovery of second generation cholesterol absorption inhibitors. Abstracts of Papers, 239th ACS National Meeting, San Francisco, CA, United States, March 21-25, 2010 2010,MEDI-285.
56. Fessard TC, Li DB, Abdelkafi H, et al. Non-systemic cholesterol absorption inhibitors. Abstracts of Papers, 239th ACS National Meeting, San Francisco, CA, United States, March 21-25, 2010 2010,MEDI-284.
57. Jaehne G, Heuer HO, Schaefer HL, et al. Canosimibe: Design, synthesis, and in vivo activity of a nonsystemic inhibitor of cholesterol absorption. Abstracts of Papers, 239th ACS National Meeting, San Francisco, CA, United States, March 21-25, 2010 2010,MEDI-283.
58. Starke I, Ostlund-Lindqvist AM: Novel potent dipeptide substituted azetidinones as cholesterol absorption inhibitors with low systemic uptake. Abstracts of Papers, 239th ACS National Meeting, San Francisco, CA, United States, March 21-25, 2010 2010,MEDI-282.
59. H: Development of KT6-971: A C-glycoside of NPC1L1 transporter inhibitor. Abstracts of Papers, 239th ACS National Meeting, San Francisco, CA, United States, March 21-25, 2010 2010,MEDI-281.
60. Dahl PK, Huval C, Holmes-Farley SR: Biologically active polymeric sequestrants:Design, synthesis, and therapeutic applications. Pure Appl.Chem 2007, 79:1521-30.
61. Braunlin W, Zhorov E, Guo A, Apruzzese W, Xu Q, Hook P, Smisek DL, Mandeville WH, Holmes-Farley SR: Bile acid binding to sevelamer HCl. Kidney Int. 2002, 62:611-9.
62. Takebayashi K, Aso Y, Inukai T: Role of bile acid sequestrants in the treatment of type 2 diabetes. World J.Diabetes 2010, 1:146-52.
63. Kramer W, Glombik H: Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs. Current Medicinal Chemistry 2006, 13:997-1016.
64. Chen L, Yao X, Young A, et al. Inhibition of Apical Sodium-Dependent Bile Acid Transporter (Asbt) as a Novel Treatment for Diabetes. Am.J.Physiol Endocrinol.Metab 2011.
65. Homan R, Krause R: Established and Emerging Strategies for Inhibition of Cholesterol Absorption. Current Pharmaceutical Design 1997,29-44.
66. Huggins KW, Boileau AC, Hui DY: Protection against diet-induced obesity and obesity- related insulin resistance in Group 1B PLA2-deficient mice. Am J Physiol Endocrinol Metab 2002, 283:E994-1001.
67. Hollie NI, Hui DY: Group 1B phospholipase A2 deficiency protects against diet-induced hyperlipidemia in mice. J.Lipid Res. 2011.
68. Labonte ED, Pfluger PT, Cash JG, et al. Postprandial lysophospholipid suppresses hepatic fatty acid oxidation: the molecular link between group 1B phospholipase A2 and diet-induced obesity. FASEB J. 2010, 24:2516-24.
69. Hui DY, Cope MJ, Labonte ED, et al. The phospholipase A(2) inhibitor methyl indoxam suppresses diet-induced obesity and glucose intolerance in mice. Br.J Pharmacol 2009, 157:1263-69.
70. Chang H, Charmot D, Glinka T, et al. Inventors, Ilypsa Inc., assignee: Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors. United States Patent 7666898B2 2010.
71. Bartlett JG: Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002, 346:334-339.
72. Kelly CP, Pothoulakis C, LaMont JT: Clostridium difficle colitis. N Engl J Med 1994, 330:257-262.
73. Triadafilopoulos G, Pothoulakis C, O'Brien MJ, LaMont JT: Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology 1987, 93:273-9.
74. Kyne L, Hamel MB, Polavaram R, Kelly CP: Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002, 34:346-53.
75. Kurtz CB, Cannon EP, Brezzani A, et al. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob.Agents Chemother. 2001, 45:2340-7.
76. Braunlin W, Xu Q, Hook P, et al. Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea. Biophys J 2004, 87:534-9.
77. Davies AH, Roberts AK, Shone CC, Acharya KR: Super toxins from a super bug: structure and function of Clostridium difficile toxins. Biochem.J. 2011, 436:517-26.
78. Heerze LD, Kelm MA, Talbot JA, Armstrong GD: Oligosaccharide sequences attached to an inert support (SYNSORB) as potential therapy for antibiotic-associated diarrhea and pseudomembranous colitis. J Infect Dis 1994, 169:1291-6.
79. Mong TK, Charmot D, Buysse JM, Chang H, Cope MJ, Goka E, inventors, Ilypsa Inc, Assignee: Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle. WO2006044577A1 2006.
80. Louie T, Miller M, Donskey C, Mullane K, Goldstein EJ: Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob.Agents Chemother. 2009, 53:223-8.
81. Duggan ST: Fidaxomicin: In Clostridium difficile Infection. Drugs 2011, 71:2445-56.
82. Caradonna L, Amati L, Magrone T, Pellegrino NM, Jirillo E, Caccavo D: Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance. J.Endotoxin Res.FIELD Full Journal Title:Journal of Endotoxin Research 2000, 6:205-14.
83. Solga SF, Diehl AM: Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol 2003, 38:681-7.
84. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56:1761-72.
85. Krack A, Sharma R, Figulla HR, Anker SD: The importance of the gastrointestinal system in the pathogenesis of heart failure. European Heart Journal 2005, 26:2368-74.
86. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006, 12:1365-71.
87. Pharma: Alkaline phosphatase for treatment of ulcerative colitis.http://www.am-pharma.com/download/090506%20alkaline%20phosphatase%20in%20uc%20may2009.pdf 2007.
88. Shan L, Qiao SW, Rentz-Hansen H, et al. Identification and analysis of multivalent proteolytically resistant peptides from gluten: implications for celiac sprue. J.Proteome.Res. 2005, 4:1732-41.
89. Leroux JC, Nasser Eddine M, Inventors, University of Montreal Canada, Assignee: Pharmaceutical compositions comprising polymeric binders with non-hydrolyzable covalent bonds and their use in treating celiac disease. WO2007053935A1 2007.
90. Siegel M, Garber ME, Spencer AG, Botwick W, Kumar P, Williams RN, et al. Safety, Tolerability, and Activity of ALV003: Results from Two Phase 1 Single, Escalating-Dose Clinical Trials. Dig.Dis.Sci. 2011.
91. Lahdeaho M, Maki M, Kaukinen K, Laurila K, Marcantonio A, Adelman DC: ALV003, a novel glutenase, attenuates gluten-induced small intestinal mucosal injury in celiac disease patients: a randomized controlled phase 2a clinical trial. http://uegw.congress-online.com/guest/ID089e48b3490d24/AbstractView?ABSID=1440 8 2011.
92. Drago S, El AR, Di PM, et al. Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand.J Gastroenterol 2006, 41:408-19.
93. Paterson BM, Lammers KM, Arrieta MC, Fasano A, Meddings JB: The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment.Pharmacol.Ther. 2007, 26:757-66.
94. Niwa T, Ise M: Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J.Lab Clin.Med. 1994, 124:96-104.
95. Niwa T, Aoyama I, Takayama F, et al. Urinary indoxyl sulfate is a clinical factor that affects the progression of renal failure. Miner.Electrolyte Metab 1999, 25:118-22.
96. Niwa T: Indoxyl sulfate is a nephro-vascular toxin. J.Ren Nutr. 2010,20:S2-6.
97. Motojima M, Hosokawa A, Yamato H, Muraki T, Yoshioka T: Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int. 2003, 63:1671-80.
98. Niwa T, Tsukushi S, Ise M, et al. Indoxyl sulfate and progression of renal failure: effects of a low-protein diet and oral sorbent on indoxyl sulfate production in uremic rats and undialyzed uremic patients. Miner.Electrolyte Metab 1997, 23:179-84.
99. Nakamura T, Sato E, Fujiwara N, et al. Oral adsorbent AST-120 ameliorates tubular injury in chronic renal failure patients by reducing proteinuria and oxidative stress generation. Metabolism 2011,60:260-64.
100. Akizawa T, Asano Y, Morita S, et al. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am.J.Kidney Dis. 2009, 54:459-67.
101. Maeda K, Hamada C, Hayashi T, et al. Long-term effects of the oral adsorbent, AST-120, in patients with chronic renal failure. J.Int.Med.Res. 2009, 37:205-13.
102. Henle T: Protein-bound advanced glycation end-products (AGEs) as bioactive amino acid derivatives in foods. Amino.Acids 2005, 29:313-22.
103. Uribarri J, Peppa M, Cai W, et al. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am.J.Kidney Dis. 2003, 42:532-8.
104. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C, Vlassara H: Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J.Am.Soc.Nephrol. 2003, 14:728-31.
105. Ueda S, Yamagishi S, Takeuchi M, et al. Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure. Mol.Med. 2006, 12:180-4.
106. Kakuta T, Tanaka R, Hyodo T, et al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am.J.Kidney Dis. 2011, 57:422-31.
107. Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003, 63:1934-43.
108. Glorieux G, Vanholder R: New uremic toxins - which solutes should be removed? Contrib.Nephrol. 2011, 168:117-28.
109. Costello JF, Smith M, Stolarski C, Sadovnic MJ: Extrarenal clearance of oxalate increases with progression of renal failure in the rat. J.Am.Soc.Nephrol. 1992, 3:1098-104.
110. Grujic D, Salido EC, Shenoy BC, et al. Hyperoxaluria is reduced and nephrocalcinosis prevented with an oxalate-degrading enzyme in mice with hyperoxaluria. Am.J.Nephrol. 2009, 29:86-93.
111. Brandt LJ, Prather CM, Quigley EM, Schiller LR, Schoenfeld P, Talley NJ: Systematic review on the management of chronic constipation in North America. Am.J.Gastroenterol. 2005, 100 Suppl 1:S5-21.
112. Higgins PD, Johanson JF: Epidemiology of constipation in North America: a systematic review. Am.J.Gastroenterol. 2004, 99:750-59.
113. Bouchoucha M, Devroede G, Dorval E, Faye A, Arhan P, Arsac M: Different segmental transit times in patients with irritable bowel syndrome and normal colonic transit time: is there a correlation with symptoms? Tech.Coloproctol. 2006, 10:287-96.
114. Seidl H, Gundling F, Pehl C, Pfeiffer A, Schepp W, Schmidt T: Small bowel motility in functional chronic constipation. Neurogastroenterol.Motil. 2009.
115. Bryant AP, Busby RW, Bartolini WP, et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci. 2010.
116. Pilot Study on the Effect of Linaclotide in Patients With Chronic Constipation. Am.J.Gastroenterol. 2009, 104:125-32.
117. Johnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 2010, 139:1877-86.
118. Spencer AG, Jacobs J, Leadbetter MR, et al. RDX5791, a First-in-Class Minimally Systemic NHE3 Inhibitor in Clinical Development for CIC and IBS-C, Increases Intestinal Sodium Leading to Enhanced Intestinal Fluid Volume and Transit. Proceedings of the Drug Disease Week 2011 Chicago Gastroenterology 2011, 140:S-99.
119. Rosenbaum DP, Spencer AG, Jacobs J, Charmot D: The Safety, Tolerability, Systemic Exposure, and Effect on Bowel Habits of Single and Multiple Doses of the Intestinal Sodium Re-Uptake Inhibitor RDX5791 in Normal Healthy Volunteers. Proceeding of the ACG meeting 2011 Washington DC American Journal of Gastroenterology 2011, 106:S504.
120. Eutamene E, Charmot D, Navre M, Bueno L: Visceral Antinociceptive Effects of RDX5791, a First-in-Class Minimally Systemic NHE3 Inhibitor on Stress-Induced Colorectal Hypersensitivity to Distension in Rats. Proceedings of the DDW meeting 2011 Chicago IL Gastroenterology 2011, 140:S57-S58.
121. Eutamene H, Bradesi S, Larauche M, et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol.Motil. 2010, 22:e312-e384.
122. Chey WD, Camilleri M, Chang L, Rikner L, Graffner H: A randomized placebo-controlled phase IIb trial of a3309, a bile Acid transporter inhibitor, for chronic idiopathic constipation. Am J.Gastroenterol. 2011, 106:1803-1812.
123. EPIX Pharmaceuticals: EPX-16006 - a potential first-in-class, highly selective, oral, non-absorbed, small molecule P2Y2 agonist for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation. http://www.drugs.com/clinical_trials/epix-pharmaceuticals-announces-discontinuation-prx-00023-clinical-development-program-3629.html 2008.
124. Donowitz M, Singh S, Singh P, et al. Alterations in the proteome of the NHERF1 knockout mouse jejunal brush border membrane vesicles. Physiol Genomics 2010, 42A:200-10.
125. Donowitz M, Singh S, Salahuddin FF, et al. Proteome of murine jejunal brush border membrane vesicles. J.Proteome.Res. 2007, 6:4068-79.
126. Vetter ML, Cardillo S, Rickels MR, Iqbal N: Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann.Intern.Med. 2009, 150:94-103.
127. Rhee NA, Vilsboll T, Knop FK: Current evidence for a role of GLP-1 in Roux-en-Y gastric bypass-induced remission of type 2 diabetes. Diabetes Obes.Metab 2011.
128. Hansen EN, Tamboli RA, Isbell JM, et al. Role of the foregut in the early improvement in glucose tolerance and insulin sensitivity following Roux-en-Y gastric bypass surgery. Am.J.Physiol Gastrointest.Liver Physiol 2011, 300:G795-802.
129. Thomas C, Auwerx J, Schoonjans K: Bile acids and the membrane bile acid receptor TGR5--connecting nutrition and metabolism. Thyroid 2008, 18:167-74.
130. Chu ZL, Carroll C, Alfonso J, et al. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release. Endocrinology 2008, 149:2038-47.
131. Bueno L: Protease activated receptor 2: a new target for IBS treatment. Eur Rev.Med.Pharmacol.Sci. 2008, 12 Suppl 1:95-102.
132. Lohman RJ, Cotterell AJ, Suen JY, Liu L, Do TA, Vesey DA, Fairlie DP: Antagonism of protease activated receptor 2 protects against experimental colitis. J.Pharmacol.Exp.Ther. 2011.
133. Dalmasso G, Nguyen HT, Ingersoll SA, et al. The PepT1-NOD2 Signaling Pathway Aggravates Induced Colitis in Mice. Gastroenterology 2011, 141:1334-45.
134. Dalmasso G, Nguyen HT, Charrier-Hisamuddin L, et al. PepT1 mediates transport of the proinflammatory bacterial tripeptide L- Ala-{gamma}-D-Glu-meso-DAP in intestinal epithelial cells. Am.J.Physiol Gastrointest.Liver Physiol 2010, 299:G687-96.
135. Sartor RB: Microbial influences in inflammatory bowel diseases. Gastroenterology 2008, 134:577-594.
136. Geibel JP, Hebert SC: The functions and roles of the extracellular Ca2+-sensing receptor along the gastrointestinal tract. Annu.Rev.Physiol 2009, 71:205-17.
137. Sonawane ND, Hu J, Muanprasat C, Verkman AS: Luminally active, nonabsorbable CFTR inhibitors as potential therapy to reduce intestinal fluid loss in cholera. FASEB J 2006, 20:130-2.
138. Sonawane ND, Zhao D, Zegarra-Moran O, Galietta LJ, Verkman AS: Lectin conjugates as potent, nonabsorbable CFTR inhibitors for reducing intestinal fluid secretion in cholera. Gastroenterology 2007, 132:1234-44.
139. Tradtrantip L, Namkung W, Verkman AS. Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels. Mol.Pharmacol. 2010, 77:69-78.